Cargando…

Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer

The standard treatment for ductal carcinoma in situ (DCIS) of the breast is surgical resection, followed by radiation. Here, we tested localized therapy of DCIS in mice using the immunoconjugate (225)Ac linked-trastuzumab delivered through the intraductal (i.duc) route. Trastuzumab targets HER-2/neu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Takahiro, Jin, Kideok, Song, Hong, Park, Sunju, Huso, David L., Zhang, Zhe, Liangfeng, Han, Zhu, Charles, Bruchertseifer, Frank, Morgenstern, Alfred, Sgouros, George, Sukumar, Saraswati
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078096/ https://www.ncbi.nlm.nih.gov/pubmed/27119227 http://dx.doi.org/10.18632/oncotarget.8949

Ejemplares similares

Preclinical Targeted α- and β(−)-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
por: Puttemans, Janik, et al.
Publicado: (2020)

Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model
por: Nedrow, Jessie R., et al.
Publicado: (2017)

BRCA1: linking HOX to breast cancer suppression
por: Jin, Kideok, et al.
Publicado: (2010)

A pivotal role for HOXB7 protein in endocrine resistant breast cancer
por: Jin, Kideok, et al.
Publicado: (2015)

Internal microdosimetry of alpha-emitting radionuclides
por: Hofmann, Werner, et al.
Publicado: (2019)

Functionalized TiO(2) nanoparticles labelled with (225)Ac for targeted alpha radionuclide therapy
por: Cędrowska, Edyta, et al.
Publicado: (2018)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer—a preclinical study
por: Wang, Guannan, et al.
Publicado: (2022)

Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer
por: Sreekumar, Sreeja, et al.
Publicado: (2023)

Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
por: Wulbrand, Christian, et al.
Publicado: (2013)

A Review of the Occurrence of Alpha-Emitting Radionuclides in Wild Mushrooms
por: Strumińska-Parulska, Dagmara, et al.
Publicado: (2020)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer
por: Park, Sunju, et al.
Publicado: (2017)

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2018)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

Bioaccumulation of gamma emitting radionuclides in Polysiphonia fucoides
por: Zalewska, Tamara
Publicado: (2013)

Inhibitors of STAT3, β‐catenin, and IGF‐1R sensitize mouse PIK3CA‐mutant breast cancer to PI3K inhibitors
por: Merino, Vanessa F., et al.
Publicado: (2017)

Protection from contamination by (211)At, an enigmatic but promising alpha-particle-emitting radionuclide
por: Ohnuki, Kazunobu, et al.
Publicado: (2022)

ADP Ribosylation by PARP-1 Suppresses HOXB7 Transcriptional Activity
por: Wu, Xinyan, et al.
Publicado: (2012)

MIND the translational gap: Preclinical models of ductal carcinoma in situ
por: Hutten, Stefan J., et al.
Publicado: (2023)

The Simulation of In-Situ Groundwater Detector Response as a Means of Identifying Beta Emitting Radionuclides by Linear Regression Analysis
por: Turkington, Graeme, et al.
Publicado: (2021)

Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides
por: Li, Wei Bo, et al.
Publicado: (2022)

(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
por: Kratochwil, C., et al.
Publicado: (2014)

Intraductal pegylated liposomal doxirubicin may achieve long term protection in HER2/NEU transgenic mice by restricting mammary gland outgrowth
por: Sukumar, S, et al.
Publicado: (2009)

Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis
por: Lee, Esak, et al.
Publicado: (2014)

Targeted alpha therapy for glioblastoma
por: Kunikowska, Jolanta, et al.
Publicado: (2022)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
por: Estévez, Laura G, et al.
Publicado: (2014)

Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
por: Chan, Ho Sze, et al.
Publicado: (2016)

Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression
por: Smith, Yvonne E., et al.
Publicado: (2022)

Risk of Lung Cancer Mortality in Nuclear Workers from Internal Exposure to Alpha Particle-emitting Radionuclides
por: Grellier, James, et al.
Publicado: (2017)

Functionalized NaA nanozeolites labeled with (224,225)Ra for targeted alpha therapy
por: Piotrowska, Agata, et al.
Publicado: (2013)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Global experience with PSMA-based alpha therapy in prostate cancer
por: Sathekge, Mike M., et al.
Publicado: (2021)

Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells
por: Agahozo, Marie Colombe, et al.
Publicado: (2021)

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model
por: Merkx, Robin I. J., et al.
Publicado: (2022)

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy
por: Puttemans, Janik, et al.
Publicado: (2022)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

Concurrent Granulomatous Mastitis and Ductal Carcinoma In Situ
por: Yoshida, Nana, et al.
Publicado: (2023)

Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling
por: Pradeep, Chaluvally-Raghavan, et al.
Publicado: (2011)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fb12uiqgenjaqde5un8cmmaurg